Subcutaneous blinatumomab plus TKI drives high remission in relapsed Ph+ acute lymphoblastic leukaemia
Subcutaneous blinatumomab plus TKI drives high remission in relapsed Ph+ acute lymphoblastic leukaemia
ATG vs PTCy for GVHD prophylaxis in AlloHCT shows improved survival in donor haematopoietic cell transplantation
Arsenic trioxide plus all trans retinoic acid improves QoL and reduces fatigue in high risk acute promyelocytic leukaemia
Pirtobrutinib plus venetoclax rituximab improves PFS in previously treated CLL and SLL
Selinexor plus ruxolitinib improves spleen response and survival in Janus kinase inhibitor naïve myelofibrosis
Fatigue in adult ITP is common despite adequate platelet counts and minimal bleeding
Surovatamig plus rituximab induces high complete response rates in previously untreated follicular lymphoma
Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in acute ITP in 1L treatment during COVID 19
CLL TIM risk model predicts infection and treatment need in newly diagnosed chronic lymphocytic leukaemia
Risk model predicts relapse after frontline blinatumomab in paediatric B-ALL
Epcoritamab induces deep and durable responses in chemotherapy-ineligible elderly patients with diffuse large B-cell lymphoma
Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma